Posters/Publications

poster

Denifanstat, a fatty acid synthase inhibitor, achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data

2026 Fall Clinical Dermatology Conference

Date - 10/2026

poster

Denifanstat for Moderate-to-Severe Acne Vulgaris: Results from an Open-label, Multicenter, Phase III Extension Study

European Academy of Dermatology and Venereology (EADV) Congress 2026

Date - 10/2026

poster

Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase (FASN) inhibitor and resmetirom combination in LDL receptor knockout MASH mice

EASL International Liver Congress

Date - 05/2026

poster

Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial

EASL International Liver Congress

Date - 05/2026

poster

Fatty acid synthase (FASN) inhibitors decreased sebum lipids in human sebocytes via inhibition of de novo lipogenesis, supporting FASN as a target for acne treatment

Society for Investigative Dermatology

Date - 05/2026

presentation

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

Keystone Symposia

Date - 04/2026

poster

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

Keystone Symposia

Date - 04/2026

poster

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial

MASH TAG

Date - 01/2026

poster

Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial

AASLD The Liver Meeting

Date - 11/2025

poster

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial

AASLD The Liver Meeting

Date - 11/2025